Has anyone been charting Tucaman's data? Started to go through old posts, but if anyone else already has that data summarized, and would be willing to share it, I would appreciate it.
My impression is the rate of script growth is not accelerating as the Covid restrictions have been loosening.
Short term, prescription growth and revenue growth is the only thing this company appears to have to stimulate share price.
Market Data 
Markets 
AI
